TXMD News 4.90 Therapeuticsmd Inc (TXMD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Therapeuticsmd Inc (TXMD) 4.90 $TXMD

BUYINS.NET Updates TherapeuticsMD SqueezeTrigger Report
M2 - Thu Apr 17, 8:13AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on TherapeuticsMD (NYSE MKT: TXMD) after releasing the latest short sale data through April 15, 2014. The total aggregate number of shares shorted since November 2011 is approximately 48.7 million shares. Approximately 26.22% of daily trading volume is short selling. The SqueezeTrigger price for all TXMD shares shorted is $4.91. A short squeeze is expected to begin when shares of TXMD close above the $4.91 SqueezeTrigger Price.

TherapeuticsMD Reports Positive Results of Rabbit Irritation Study for Its Estradiol Vaginal Capsule VagiCap(TM) (TX 004-HR) for Treatment of Vulvar Vaginal Atrophy (VVA)
Business Wire - Mon Apr 07, 3:05PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company" , announced today positive outcomes of a rabbit irritation study for TX 004-HR (formerly referred to as TX 12-004-HR), a rapidly acting estrogen vaginal preparation capsule (VagiCap).

BocaGreenMD Launches Prena1 Pearl(TM), the Only Generic Version of vitaMedMD's vitaPearl(TM)
Business Wire - Mon Apr 07, 6:15AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) ("TherapeuticsMD" or the "Company" , parent company of BocaGreenMD, Inc. ("BocaGreen" , announced today the launch of Prena1 Pearl, BocaGreen's generic formulation of vitaMedMD, Inc.'s newest prescription prenatal multivitamin, vitaPearl. vitaPearl is a pearl-shaped softgel that is currently the smallest complete prescription prenatal multivitamin and is the first to contain FOLMAX(TM), FePlus(TM), and pur-DHA(TM).

Analytical Notes on Health Care Equities -- Research on TherapeuticsMD, China Pharma Holdings, Pacira Pharma, and Lannett
PR Newswire - Wed Mar 26, 10:15AM CDT
The trading session on Tuesday, March 25, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,367.88, up 0.56% and the NASDAQ Composite closed at 4,234.27, up 0.19%. The S&P 500 finished the session 0.44% higher at 1,865.62. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day 0.83% higher at 671.69, while the same has advanced 5.27% in the last three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), China Pharma Holdings Inc. (NYSE MKT: CPHI), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Lannett Co. Inc. (NYSE: LCI). Free technical research on TXMD, CPHI, PCRX, and LCI can be downloaded upon signing up at:

TherapeuticsMD Announces Pricing of Secondary Offering
Business Wire - Thu Mar 20, 4:36PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company" , a women's health care product company, announced today the pricing of a previously announced underwritten secondary public offering of 9,000,000 shares of its common stock, offered at a price of $7.10 per share. All shares are offered by the selling stockholders, including certain members of management of the Company and certain of their and the Company's affiliates. The Company will not sell any shares or receive any proceeds from the offering. The offering is expected to close on or about March 26, 2014, subject to the satisfaction of customary closing conditions. In addition, certain of the selling stockholders have granted the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of common stock.

Therapeutics to offer 9m shares in secondary public offering
M2 - Wed Mar 19, 7:41AM CDT
Healthcare company Therapeutics (NYSE MKT:TXMD) reported on Tuesday that it intends to start a secondary public offering of 9,000,000 shares of its common stock.

vitaMedMD Launches vitaPearl(TM), The Smallest Complete Prescription Prenatal Multivitamin With FOLMAX(TM), FePlus(TM), and pur-DHA(TM)
Business Wire - Wed Mar 19, 6:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) ("TherapeuticsMD" or the "Company" , a women's healthcare company and parent company of vitaMedMD, LLC ("vitaMedMD" , announced today the launch of vitaMedMD's newest prescription prenatal multivitamin, vitaPearl, adding to its successful prenatal line consisting of vitaMedMD One Rx, vitaMedMD Plus Rx, and vitaMedMD RediChew(TM) Rx. vitaPearl is a pearl-shaped softgel that is currently the smallest complete prescription prenatal multivitamin and the first to contain vitaMedMD's proprietary ingredients of FOLMAX(TM) (immediate and modified release folic acid), FePlus(TM) (ferrous fumarate and ferric sodium EDTA), an iron combination containing a chelated iron, and pur-DHA(TM) (docosahexaenoic acid) among its14 vitamins and minerals.

TherapeuticsMD Announces Launch of Secondary Offering
Business Wire - Tue Mar 18, 3:02PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the "Company" today announced the launch of an underwritten secondary public offering of 9,000,000 shares of its common stock. All shares will be offered by the selling stockholders, including certain members of management of the Company and certain of their affiliates. The Company will not sell any shares or receive any proceeds from the offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, certain of the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock.

TherapeuticsMD Reports Fourth Quarter and Full-Year 2013 Results
Business Wire - Mon Mar 03, 3:05PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company, ("TherapeuticsMD" or the "Company" today announced results for the three-month period and full-year ended December 31, 2013.

TherapeuticsMD to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Tue Feb 25, 3:30PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company" , announced today that it will present at the Cowen and Company 34th Annual Health Care Conference taking place at the Boston Marriott Copley Place on March 3-5, 2014.

TherapeuticsMD To Host Conference Call and Live Audio Webcast to Disclose Financial Results for Quarter and Year Ended December 31, 2013
Business Wire - Tue Feb 25, 6:01AM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company" , will host a conference call and live audio webcast to disclose its financial results for quarter and year ended December 31, 2013. The call and webcast will be held on Monday, March 3, 2014 at 4:30pm EST and will be hosted by Robert Finizio, Co-Founder and Chief Executive Officer, and Dan Cartwright, Chief Financial Officer. Call and webcast specifics follow:

'Mad Money' Lightning Round: Don't Bet on Boyd Gaming
at The Street - Fri Jan 31, 5:00AM CST
Cramer says there's nothing special about Archer-Daniels-Midland and prefers AT&T's yield to Altria's.

Jim Cramer's 'Mad Money' Recap: Social, Mobile, Cloud Are Buys
at The Street - Thu Jan 30, 7:19PM CST
Facebook and Google shine with fantastic earnings, Cramer says.

TherapeuticsMD Reports Positive PK Study Results for Its Estradiol Vaginal Capsule VagiCap(TM) (TX 12-004-HR) for Treatment of Vulvar Vaginal Atrophy (VVA)
Business Wire - Tue Jan 28, 6:00AM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company" , announced today the final PK results from two studies of TX 12-004-HR, a rapidly acting vaginal preparation capsule versus Novo Nordisk's Vagifem(R) (estradiol vaginal tablet). ESTR-1K-499 was an open label, single dose crossover, relative bioavailability study comparing 10ug of TX 12-004-HR to 10ug of Vagifem. ESTR-1K-500 was the study with the same design, but compared 25ug of TX 12-004-HR to 25ug of Vagifem. Study results showed substantially lower systemic estradiol exposure of TX 12-004-HR when compared to Vagifem. In conjunction with the previously reported efficacy of TX 12-004-HR, this PK data suggests that TX 12-004-HR may provide therapeutic advantages over Vagifem.

Therapeutics Inc begins Phase 3 clinical trial of TX 12-002-HR for treating secondary amenorrhea in women
M2 - Mon Jan 27, 6:39AM CST
Healthcare company Therapeutics Inc (NYSE MKT:TXMD) reported on Friday the launch of the SPRY Trial to evaluate the safety and efficacy of TX 12-002-HR for the treatment of secondary amenorrhea in women.

TherapeuticsMD Initiates Phase 3 Clinical Trial of Its Progesterone Candidate (TX 12-002-HR) for Treatment of Secondary Amenorrhea
Business Wire - Fri Jan 24, 6:00AM CST
TherapeuticsMD, Inc. (NYSE MKT:TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company" , announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women. Clinical endpoints of the SPRY Trial include withdrawal bleeding and complete secretory change in three consecutive cycles. The trial is designed to enroll approximately 180 patients in the United States and is expected to be completed in late 2014.

TherapeuticsMD declares issuance of US patent covering natural combination hormone replacement formulations and therapies
M2 - Fri Jan 24, 4:34AM CST
Women's healthcare company TherapeuticsMD Inc (NYSE MKT: TXMD) announced on Wednesday the issuance of US Patent No 8,633,178 (the '178 patent) entitled 'Natural Combination Hormone Replacement Formulations and Therapies', by the US Patent and Trademark Office (USPTO).

Therapeutics wins US patent for natural combination hormone replacement formulations and therapies
M2 - Thu Jan 23, 5:25AM CST
US-based healthcare company Therapeutics Inc (NYSE MKT:TXMD) reported on Wednesday the receipt of the US Patent No. 8,633,178 (the '178 patent; U.S. Application No. 13/684,002), entitled "Natural Combination Hormone Replacement Formulations and Therapies."

TherapeuticsMD Announces Issuance of U.S. Patent Covering Natural Combination Hormone Replacement Formulations and Therapies, Including TX 12-001-HR
Business Wire - Wed Jan 22, 3:15PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company" , announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,633,178 (the '178 patent; U.S. Application No. 13/684,002), entitled "Natural Combination Hormone Replacement Formulations and Therapies." The '178 patent is expected to expire in the early 2030s and covers the Company's platform technology and TX 12-001-HR, its oral bioidentical 17B-estradiol and progesterone combination drug candidate.

Technical Dossier: Theravance, Alkermes, Cubist Pharma, and TherapeuticsMD
PR Newswire - Wed Jan 08, 7:00AM CST
On Tuesday, January 07, 2014, the U.S. equity market finished on a positive note. The S&P 500 ended the day at 1,837.88, up 0.61%; the Dow Jones Industrial Average closed at 16,530.94, up 0.64%; and the NASDAQ Composite Index finished at 4,153.18, up 0.96%. The S&P 500 Health Care Sector Index gained 1.01% to close the session at 644.13; and the S&P 500 Biotechnology Industry Index closed at 2,766.71, up 0.72%. The S&P 500 Biotechnology Industry Index has gained 10.05% in the previous three months, outperforming the S&P 500, which has gained 9.65% during the same period. Additionally, the S&P 500 Pharmaceuticals Sub Industry Index closed at 491.51, up 0.94%. The major movers in the Health Care Sector included Theravance Inc. (NASDAQ: THRX), Alkermes PLC (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and TherapeuticsMD Inc. (NYSE MKT: TXMD). All these companies are tracked by AAAResearchReports.com. Free technical research on THRX, ALKS, CBST, and TXMD can be downloaded upon signing up at:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 255

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 69

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 136

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 131

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 148

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Fold Health's AI: Revolutionizing Patient Care Dynamics

Updated Category News Views 140

AI's Role in Healthcare: From Insight to Action Healthcare's got a resource issue, plain and simple. It's like trying to fill a bathtub with a hole in it—clinicians are swamped, burnout is high, and patients aren't getting the attention they need. Enter Fold Health's AI operating layer, launched with the ambition to realign the equation. Not Just Another Tech Buzzword...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 63

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 165

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 120

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Insights from OncoHost in Lung Cancer Treatment Strategy

Updated Category News Views 149

New Advances in Understanding Lung Cancer Treatment Resistance Recent findings from OncoHost shed light on the mechanisms behind resistance to immunotherapy in patients battling lung cancer. The study presents vital insights aimed at improving therapeutic strategies through advanced plasma proteomics analysis. Insights from Advanced Plasma Proteomics OncoHost, a...

Continue Reading
Understanding Eldorado Gold's Current Market Position and P/E

Updated Category News Views 167

Analyzing Eldorado Gold Inc's Current Market Situation At present, Eldorado Gold Inc. (NYSE: EGO) shares trade at a price of $27.34, reflecting a decrease of 5.85% in the current session. This decline comes after a slight drop of 1.19% over the past month. Despite this short-term volatility, when looking over a longer timeline, the stock shows impressive growth, having...

Continue Reading
Truecaller Achieves Remarkable Growth with 450 Million Users

Updated Category News Views 218

Truecaller Reaches 450 Million Monthly Active Users Truecaller, the renowned platform dedicated to verifying contacts and blocking unwanted communications, has reached a significant milestone, surpassing 450 million active users. This achievement marks another step in its impressive growth trajectory over the last year, with around 50 million new users added in just ten...

Continue Reading
Shell plc's Recent Share Buybacks: Key Insights Revealed

Updated Category News Views 377

Overview of Shell plc's Share Buyback Activities Shell plc has recently initiated significant share buyback activities as part of its ongoing strategy to enhance shareholder value. This move demonstrates the company's commitment to investing back into itself and optimizing capital allocation. The buybacks reflect Shell's strong financial position and positive outlook on...

Continue Reading
Wyndham Hotels Investigation: Uncovering Potential $50 Million Loss

Updated Category News Views 324

Investigation into Wyndham Hotels Sparks Concern Recent findings from internal records of Wyndham Hotels & Resorts have revealed alarming information suggesting that the Royalton Letter of Credit (LOC) was fully funded but not released. This situation raises troubling questions about potential securities and franchise-law violations involving multiple parties....

Continue Reading